Figure 6

Anti-IFNAR mAb and anti-NKG2D mAb treatment ameliorated lupus disease in B6.MRL/lpr mice. (A) Comparison of the frequencies of Treg cells and NKG2D⁺CD4⁺ T cells in B6.MRL/lpr mice after 5 wk of IFNAR and NKG2D antibody treatments, as well as in healthy B6 control mice. (B) Serum level of autoantibodies (anti-dsDNA and ANA) after IFNAR and NKG2D antibody treatments in B6.MRL/lpr mice. Data in A and B are presented as mean ± SD. (C) Kidney histology (left) showing reduced glomerular hypercellularity and immune deposits (IgG, IgM and C3) after IFNAR and NKG2D antibody treatments in B6.MRL/lpr mice. Histological score and fluorescence intensity score (right) were assessed. Results are representative of three experiments with 5–6 mice per group. (D) Weights of spleen and lymph nodes (LN) after IFNAR1 and NKG2D antibody treatments in B6.MRL/lpr mice. Data are presented as mean ± SD. (E) Survival analysis for the IFNAR and NKG2D antibody treatments in B6.MRL/lpr mice, as compared with PBS treatment. Each symbol represents one individual, and data are representative of three independent experiments. ^* P < 0.05, ^** P < 0.01, ^*** P < 0.001.